14 results on '"V. Verriele"'
Number of results to display per page
Search Results
2. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei of appendicular and extra-appendicular origin
- Author
-
J-B Delhorme, F Severac, G Averous, O Glehen, G Passot, N Bakrin, F Marchal, M Pocard, R Lo Dico, C Eveno, S Carrere, O Sgarbura, F Quenet, G Ferron, D Goéré, C Brigand, J Abba, K Abboud, M Alyami, C Arvieux, G Balagué, V Barrau, H Ben Rejeb, J-M Bereder, I Berton-Rigaud, F Bibeau, I Bonnefoy, D Bouzard, I Bricault, S Carrère, C de Chaisemartin, M Chassang, A Chevallier, T Courvoisier, P Dartigues, A Dohan, J Dubreuil, F Dumont, M Faruch-Bilfeld, J Fontaine, L Fournier, J Gagniere, D Geffroy, L Ghouti, F-N Gilly, L Gladieff, A Guibal, J-M Guilloit, F Guyon, B Heyd, C Hoeffel, C Hordonneau, S Isaac, P Jourdan-Enfer, R Kaci, R Kianmanesh, C Labbé-Devilliers, J Lacroix, B Lelong, A Leroux-Broussier, Y Lherm, G Lorimier, C Malhaire, P Mariani, E Mathiotte, P Meeus, E Mery, S Msika, C Nadeau, P Ortega-Deballon, O Pellet, P Peyrat, D Pezet, N Pirro, F Poizat, J Porcheron, A Poulet, P Rat, P Rousselot, P Rousset, H Senellart, M Serrano, V Servois, O Sgabura, A Skanjeti, M Svrcek, R Tetreau, E Thibaudeau, Y Touchefeu, J-J Tuech, S Valmary-Degano, D Vaudoyer, S Velasco, V Verriele-Beurrier, L Villeneuve, R Wernert, F Zinzindohoue, CHU Strasbourg, Les Hôptaux universitaires de Strasbourg (HUS), Department of Oncologic Surgery, Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Department of oncologic surgery, Laboratoire de recherche en Hydrodynamique, Énergétique et Environnement Atmosphérique (LHEEA), École Centrale de Nantes (ECN)-Centre National de la Recherche Scientifique (CNRS), Carcinose Angiogenèse et Recherche Translationnelle, Angiogenese et recherche translationnelle (CART U965), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), CRLC Val d'Aurelle-Paul Lamarque, CRLCC Val d'Aurelle - Paul Lamarque, Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Department of Surgical Oncology Institut Claudius Regaud, Department of Surgical Oncology, Université Paris-Sud - Paris 11 (UP11), and Département de chirurgie digestive
- Subjects
Male ,medicine.medical_specialty ,[SDV]Life Sciences [q-bio] ,Gastroenterology ,Disease-Free Survival ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Pseudomyxoma peritonei ,Survival rate ,Peritoneal Neoplasms ,Survival analysis ,Urachus ,Retrospective Studies ,business.industry ,Retrospective cohort study ,Cytoreduction Surgical Procedures ,Hyperthermia, Induced ,Middle Aged ,Prognosis ,Pseudomyxoma Peritonei ,medicine.disease ,Debulking ,Survival Analysis ,3. Good health ,medicine.anatomical_structure ,Appendiceal Neoplasms ,030220 oncology & carcinogenesis ,Peritoneal Cancer Index ,Female ,030211 gastroenterology & hepatology ,Surgery ,Hyperthermic intraperitoneal chemotherapy ,business - Abstract
BackgroundThe prognostic value of the primary neoplasm responsible for pseudomyxoma peritonei (PMP) remains poorly studied. The aim of this study was to determine the prognosis for patients with extra-appendicular PMP (EA-PMP) treated optimally with complete cytoreductive surgery (CCRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).MethodsAll patients treated for PMP with CCRS and HIPEC between 1994 and 2016 were selected retrospectively from a French multicentre database. Patients with EA-PMP had pathologically confirmed non-neoplastic appendices and were matched in a 1 : 4 ratio with patients treated for appendicular PMP (A-PMP), based on a propensity score.ResultsSome 726 patients were identified, of which 61 (EA-PMP group) were matched with 244 patients (A-PMP group). The origins of primary tumours in the EA-PMP group included the ovary (45 patients), colon (4), urachus (4), small bowel (1), pancreas (1) and unknown (6). The median peritoneal carcinomatosis index was comparable in EA-PMP and A-PMP groups (15·5 versus 18 respectively; P = 0·315). In-hospital mortality (3 versus 2·9 per cent; P = 1·000) and major morbidity 26 versus 25·0 per cent; P = 0·869) were also similar between the two groups. Median follow-up was 66·9 months. The 5-year overall survival rate was 87·8 (95 per cent c.i. 83·2 to 92·5) per cent in the A-PMP group and 87 (77 to 96) per cent in the EA-PMP group. The 5-year disease-free survival rate was 66·0 (58·7 to 73·4) per cent and 70 (53 to 83) per cent respectively.ConclusionOverall and disease-free survival following treatment with CCRS and HIPEC is similar in patients with pseudomyxoma peritonei of appendicular or extra-appendicular origin.
- Published
- 2018
- Full Text
- View/download PDF
3. 821TiP GREAT: A multicentric cohort of advanced ovarian cancer (AOC) treated in real life with prospective collection of clinical data, tumor sample, and biomarkers (tBRCA, HRD) including genomic putative theranostic markers: A GINECO study
- Author
-
Etienne Rouleau, C. Nogues, Céline Callens, Bernard Asselain, Elsa Kalbacher, Dominique Berton, Olivier Collard, Laurent Arnould, Adrien Buisson, P.A. Just, V. Verriele, Isabelle Treilleux, L. Bengrine Lefevre, Véronique Becette, Manuel Rodrigues, Alain Morel, Eric Pujade-Lauraine, Guillaume Bataillon, T. de La Motte Rouge, and Romain Boidot
- Subjects
Oncology ,Advanced ovarian cancer ,medicine.medical_specialty ,business.industry ,Internal medicine ,Cohort ,medicine ,In real life ,Hematology ,business ,Tumor Sample - Published
- 2021
- Full Text
- View/download PDF
4. Immunohistochemical evaluation of two antibodies against PD-L1 and prognostic significance of PD-L1 expression in epithelioid peritoneal malignant mesothelioma: A RENAPE study
- Author
-
S. Velasco, M. Chassang, Laurence Gladieff, Jean-Marc Guilloit, Frédéric Dumont, Thomas Courvoisier, Magali Svrcek, E. Mery, Jack Porcheron, Pablo Ortega-Deballon, V. Barrau, M. Serrano, Pierre Meeus, H. Senellart, Cécile Brigand, R. Kianmanesh, I. Bricault, M. Capovilla, O. Pellet, I. Bonnefoy, B. Lelong, A. Poulet, A. Chevallier, Delphine Vaudoyer, Frédéric Guyon, Julien Dubreuil, G. Ferron, S. Valmary-Degano, D. Geffroy, Franck Zinzindohoué, François-Noël Gilly, Laure Fournier, G. Lang Averous, Jean-Jacques Tuech, Catherine Arvieux, Karine Abboud, P. Rousselot, Y. Touchefeu, Guillaume Passot, R. Tetreau, Christine Hoeffel, Peggy Dartigues, Julio Abba, A. Dohan, Frédéric Bibeau, P. Peyrat, Naoual Bakrin, O. Sgabura, J.M. Bereder, Bruno Heyd, J. Lacroix, Frédéric Marchal, Johan Gagnière, Clarisse Eveno, J. Hommell-Fontaine, P. Rat, P. Jourdan-Enfer, C. Labbé-Devilliers, C. de Chaisemartin, Prudence Colpart, L. M'Hamdi, S. Carrere, Denis Pezet, D. Bouzard, R. Lo Dico, Marc Pocard, Gérard Lorimier, A. Leroux-Broussier, Cédric Nadeau, V. Verriele-Beurrier, François Quenet, Caroline Malhaire, S. Isaac, Nicolas Pirro, C. Hordonneau, Olivier Glehen, Clarisse Dromain, R. Kaci, L. Ghouti, E. Mathiotte, Vincent Servois, Mohammad Alyami, Pascale Mariani, H. Ben Rejeb, A. Guibal, S. Msika, Laurent Villeneuve, Romuald Wernert, F. Monnien, Diane Goéré, Emilie Thibaudeau, M. H. Laverrière, G. Balague, F. Poizat, M. Faruch-Bilfeld, Andrea Skanjeti, I. Berton-Rigaud, Yoann Lherm, Université Bourgogne Franche-Comté [COMUE] (UBFC), Pathology Department, CHU Besançon, Besançon, Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon), Hospices Civils de Lyon, Departement de Neurologie (HCL), Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital de Hautepierre [Strasbourg], Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU), Centre Hospitalier Universitaire [Grenoble] (CHU), Centre Paul Papin(Angers), Institut Bergonié [Bordeaux], UNICANCER, Department of Oncologic Surgery, Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Departement of pathology, CHU Pontchaillou [Rennes], Service central de radiologie et d'imagerie médicale, CHU Grenoble-Hôpital Michallon, Gestes Medico-chirurgicaux Assistés par Ordinateur (TIMC-IMAG-GMCAO), Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications, Grenoble - UMR 5525 (TIMC-IMAG), Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Département de chirurgie digestive, CHU Strasbourg, CRLC Val d'Aurelle-Paul Lamarque, CRLCC Val d'Aurelle - Paul Lamarque, Département de chirurgie digestive [Institut Paoli Calmettes], Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Department of Radiology, Université Paris-Sud - Paris 11 (UP11), Laboratoire de Mécanique des Systèmes et des Procédés (LMSP), Université d'Orléans (UO)-Centre National de la Recherche Scientifique (CNRS), Carcinose Angiogenèse et Recherche Translationnelle, Angiogenese et recherche translationnelle (CART U965), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Surgical Oncology Institut Claudius Regaud, Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Ciblage thérapeutique en Oncologie (EA3738), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Department of Surgical Oncology, Dept. of Nucl. Med., Jean Minjoz Univ. Hosp., Besancon, Centre Hospitalier Universitaire de Reims (CHU Reims), CRLCC René Gauducheau, Service de chirurgie thoracique cardiaque et vasculaire [Rennes], Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Center Paul Papin, Laboratoire de physique de la matière (LPM), Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de recherche en Hydrodynamique, Énergétique et Environnement Atmosphérique (LHEEA), École Centrale de Nantes (ECN)-Centre National de la Recherche Scientifique (CNRS), Institut Curie [Paris], Université de Lyon, Hôpital Louis Mourier - AP-HP [Colombes], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Chirurgie Digestive, Cancérologique, Générale, Endocrinienne et Urgences (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Department of oncologic surgery, Department of nuclear Imaging, CHU Clermont-Ferrand, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Service d'hépato-gastro-entérologie, CHU Saint-Etienne, Equipe Avenir. University of Burgundy, Univers, Transport, Interfaces, Nanostructures, Atmosphère et environnement, Molécules (UMR 6213) (UTINAM), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre National de la Recherche Scientifique (CNRS)-Institut national des sciences de l'Univers (INSU - CNRS), Service de Pathologie [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université-Sorbonne Université, Service d'Oncologie Médicale Thoracique et Digestive [CHU Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Service de Médecine nucléaire, biophysique, isotopes [CHRU Besançon], Service de chirurgie thoracique cardiaque et vasculaire [Rennes] = Thoracic and Cardiovascular Surgery [Rennes], Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), and Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)
- Subjects
Male ,Mesothelioma ,PD-L1 ,Pathology ,medicine.medical_specialty ,Survival ,Antibodies, Neoplasm ,[SDV]Life Sciences [q-bio] ,B7-H1 Antigen ,Epithelioid subtype ,03 medical and health sciences ,0302 clinical medicine ,Immune system ,Biomarkers, Tumor ,medicine ,Humans ,Lymphocytes ,030212 general & internal medicine ,Peritoneal Neoplasms ,Retrospective Studies ,Immunity, Cellular ,biology ,business.industry ,General Medicine ,Middle Aged ,Prognosis ,medicine.disease ,Immunohistochemistry ,Peritoneal Malignant Mesothelioma ,3. Good health ,Survival Rate ,Oncology ,030220 oncology & carcinogenesis ,biology.protein ,Peritoneal mesothelioma ,Biomarker (medicine) ,Female ,Surgery ,Hyperthermic intraperitoneal chemotherapy ,France ,Antibody ,business ,Follow-Up Studies - Abstract
Background Epithelioid peritoneal malignant mesothelioma (EPMM) is the most common subtype of this aggressive tumor. We compared two antibodies against PD-L1, a recent theranostic biomarker, and evaluated the prognostic value of PD-L1 expression by mesothelial and immune cells in EPMM. Methods Immunohistochemistry was performed on 45 EPMM. Clinical and pathological data were extracted from the RENAPE database. Using E1L3N and SP142 clones, inter-observer agreement, PD-L1 expression by mesothelial and immune cells and inter-antibody agreement were evaluated. The prognostic relevance of PD-L1 expression was evaluated in 39 EPMM by univariate and multivariate analysis of overall survival (OS) and progression-free survival (PFS). Results Inter-observer agreement on E1L3N immunostaining was moderate for mesothelial and immune cells, and fair for mesothelial and poor for immune cells using SP142. Using E1L3N, 31.1% of mesothelial and 15.6% of immune cells expressed PD-L1, and 22.2% of mesothelial and 26.7% of immune cells using SP142. Inter-antibody agreement was moderate. In most positive cases, 1–5% of tumor cells were positive. Using E1L3N, PD-L1 expression by lymphocytes was associated with better OS and PFS by both univariate and multivariate analysis. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy predicted better prognosis than other treatments. Solid subtype was an independent prognostic factor for worse OS. Conclusion E1L3N appeared easier to use than SP142 to evaluate PD-L1 expression. A minority of EPMM expressed PD-L1, and only a few cells were positive. PD-L1 expression by immune cells evaluated with E1L3N was an independent prognostic factor in EPMM.
- Published
- 2017
- Full Text
- View/download PDF
5. Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial
- Author
-
Denis Moro-Sibilot, Renaud Sabatier, Alexis B. Cortot, Gérard Zalcman, S.D. Guibert, Fabrice Barlesi, Maurice Pérol, J. Otto, Ratislav Bahleda, Gilles Vassal, P.J. Souquet, Marta Jimenez, Nathalie Cozic, Gilbert Ferretti, Bertrand Mennecier, N. Hoog-Labouret, S. Bota, Marie Wislez, F. De Fraipont, Véronique Haddad, Julien Mazieres, C. Dubos, V. Verriele, Isabelle Monnet, Institut d'oncologie/développement Albert Bonniot de Grenoble (INSERM U823), Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-EFS-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de biostatistique et d'épidémiologie (SBE), Direction de la recherche clinique [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Département cancer environnement (Centre Léon Bérard - Lyon), Centre Léon Bérard [Lyon], Service de pneumologie [Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] (UNICANCER/CAL), UNICANCER-Université Côte d'Azur (UCA), Service de pneumologie [Centre Hospitalier Lyon Sud - HCL], Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Intergroupe Francophone de Cancérologie Thoracique [Paris] (IFCT), Intergroupe Francophone de Cancérologie thoracique, Service d'oncologie multidisciplinaire innovations thérapeutiques [Hôpital Nord - APHM], Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital Nord [CHU - APHM], Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service de Pneumologie [CHI Créteil], CHI Créteil, Service de pneumologie, oncologie thoracique et soins intensifs respiratoires [Rouen], Hôpital Charles Nicolle [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Laboratoire de Bactériologie CHU de Rouen, Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut Gustave Roussy (IGR), CHU Toulouse [Toulouse]-Hôpital Larrey [Toulouse], CHU Toulouse [Toulouse], Service de Pneumologie - Oncologie Thoracique - Maladies Pulmonaires Rares [CHU Tenon], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU), and Hôpital Charles Nicolle [Rouen]-CHU Rouen
- Subjects
0301 basic medicine ,Oncology ,Male ,Oncogene Proteins, Fusion ,medicine.medical_treatment ,[SDV]Life Sciences [q-bio] ,ROS1 fusion ,Phases of clinical research ,Targeted therapy ,0302 clinical medicine ,Carcinoma, Non-Small-Cell Lung ,Molecular Targeted Therapy ,Aged, 80 and over ,Gene Rearrangement ,Hematology ,Middle Aged ,Protein-Tyrosine Kinases ,Proto-Oncogene Proteins c-met ,targeted therapy ,Progression-Free Survival ,3. Good health ,030220 oncology & carcinogenesis ,Cohort ,Female ,medicine.drug ,Adult ,medicine.medical_specialty ,[SDV.BC]Life Sciences [q-bio]/Cellular Biology ,Disease-Free Survival ,03 medical and health sciences ,Internal medicine ,Proto-Oncogene Proteins ,medicine ,ROS1 ,Humans ,Lung cancer ,Protein Kinase Inhibitors ,Aged ,crizotinib ,Crizotinib ,business.industry ,c-MET-mutation ,Cancer ,medicine.disease ,c-MET amplification ,Clinical trial ,lung cancer ,030104 developmental biology ,Mutation ,business - Abstract
Background In 2013, the French National Cancer Institute initiated the AcSe program to provide patients with secure access to targeted therapies outside of their marketed approvals. Efficacy and safety was then assessed using a two-stage Simon phase II trial design. When the study design was designed, crizotinib was approved only as monotherapy for adults with anaplastic lymphoma kinase plus non-small-cell lung cancers (NSCLC). Patients and methods Advanced NSCLC patients with c-MET ≥6 copies, c-MET-mutated, or ROS-1-translocated tumours were enrolled in one of the three cohorts. Patients were treated with crizotinib 250 mg twice daily. Efficacy was assessed using the objective response rate (ORR) after two cycles of crizotinib as primary outcome. Secondary outcomes included disease control rate at four cycles, best ORR, progression-free survival, overall survival, and drug tolerance. Results From August 2013 to March 2018, 5606 patients had their tumour tested for crizotinib targeted molecular alterations: 252 patients had c-MET ≥6 copies, 74 c-MET-mutation, and 78 ROS-1-translocated tumour. Finally, 25 patients in the c-MET ≥6 copies cohort, 28 in the c-MET-mutation cohort, and 37 in the ROS-1-translocation cohort were treated in the phase II trial. The ORR was 16% in the c-MET ≥6 copies cohort, 10.7% in the mutated, and 47.2% in the ROS-1 cohort. The best ORR during treatment was 32% in the c-MET-≥6 copies cohort, 36% in the c-MET-mutated, and 69.4% in the ROS-1-translocation cohort. Safety data were consistent with that previously reported. Conclusions Crizotinib activity in patients with ROS1-translocated tumours was confirmed. In the c-MET-mutation and c-MET ≥6 copies cohorts, despite insufficient ORR after two cycles of crizotinib, there are signs of late response not sufficient to justify the development of crizotinib in this indication. The continued targeting of c-MET with innovative therapies appears justified. Clinical trial number NCT02034981.
- Published
- 2019
- Full Text
- View/download PDF
6. Diffuse malignant peritoneal mesothelioma: Evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database
- Author
-
V. Kepenekian, D. Elias, G. Passot, E. Mery, D. Goere, D. Delroeux, F. Quenet, G. Ferron, D. Pezet, J.M. Guilloit, P. Meeus, M. Pocard, J.M. Bereder, K. Abboud, C. Arvieux, C. Brigand, F. Marchal, J.M. Classe, G. Lorimier, C. De Chaisemartin, F. Guyon, P. Mariani, P. Ortega-Deballon, S. Isaac, C. Maurice, F.N. Gilly, O. Glehen, G. Averous, F. Bibeau, D. Bouzard, A. Chevallier, S. Croce, P. Dartigues, S. Durand-Fontanier, L. Gouthi, B. Heyd, R. Kaci, R. Kianmanesh, M.H. Laverrière, E. Leblanc, B. Lelong, A. Leroux, V. Loi, C. Mariette, S. Msika, P. Peyrat, N. Pirro, J. Paineau, F. Poizat, J. Porcheron, P. Rat, J.M. Regimbeau, E. Thibaudeau, J.J. Tuech, S. Valmary-Degano, V. Verriele, P. Zerbib, and F. Zinzindohoue
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,Population ,computer.software_genre ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,education ,Chemotherapy ,education.field_of_study ,Database ,business.industry ,Hazard ratio ,Retrospective cohort study ,Perioperative ,medicine.disease ,Confidence interval ,3. Good health ,030220 oncology & carcinogenesis ,Peritoneal mesothelioma ,030211 gastroenterology & hepatology ,Hyperthermic intraperitoneal chemotherapy ,business ,computer - Abstract
Purpose: Diffuse malignant peritoneal mesothelioma (DMPM) is a severe disease with mainly locoregional evolution. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) is the reported treatment with the longest survival. The aim of this study was to evaluate the impact of perioperative systemic chemotherapy strategies on survival and postoperative outcomes in patients with DMPM treated with curative intent with CRS-HIPEC, using a multi-institutional database: the French RENAPE network. Patients and methods: From 1991 to 2014, 126 DMPM patients underwent CRS-HIPEC at 20 tertiary centres. The population was divided into four groups according to perioperative treatment: only neoadjuvant chemotherapy (NA), only adjuvant chemotherapy (ADJ), perioperative chemotherapy (PO) and no chemotherapy before or after CRS-HIPEC (NoC). Results: All groups (NA: n Z 42; ADJ: n Z 16; PO: n Z 16; NoC: n Z 48) were comparable regarding clinicopathological data and main DMPM prognostic factors. After a median follow-up of 61 months, the 5-year overall survival (OS) was 40%, 67%, 62% and 56% in NA, ADJ, PO and NoC groups, respectively (P Z 0.049). Major complications occurred for 41%, 45%, 35% and 41% of patients from NA, ADJ, PO and NoC groups, respectively (P Z 0.299). In multivariate analysis, NA was independently associated with worse OS (hazard ratio, 2.30; 95% confidence interval, 1.07e4.94; P Z 0.033). Conclusion: This retrospective study suggests that adjuvant chemotherapy may delay recurrence and improve survival and that NA may impact negatively the survival for patients with DMPM who underwent CRS-HIPEC with curative intent. Upfront CRS and HIPEC should be considered when achievable, waiting for stronger level of scientific evidence.
- Published
- 2016
- Full Text
- View/download PDF
7. A new internet tool to report peritoneal malignancy extent. PeRitOneal MalIgnancy Stage Evaluation (PROMISE) application
- Author
-
François Quenet, Frédéric Marchal, François-Noël Gilly, Laurent Villeneuve, Jean-Marc Guilloit, M. Carretier, S. Carrere, Clarisse Eveno, Julien Fontaine, Faheez Mohamed, Delphine Vaudoyer, S. Isaac, A. Chevallier, A. Dohan, Cécile Brigand, P. Rousset, F. Poizat, Peggy Dartigues, Julio Abba, Frédéric Dumont, Nicolas Pirro, C. Petorin, Frédéric Guyon, G. Lang-Averous, S. Evrard, Gérard Lorimier, Karine Abboud, P. Rat, E. Mery, G. Pourcher, Jack Porcheron, Pablo Ortega-Deballon, M. Messager, Rea Lo Dico, Nicolas Goasguen, Pierre Meeus, R. Tetreau, Houda Ben Rejeb, S. Durand-Fontanier, P. Peyrat, A. Mariani, Dominique Elias, D. Bouzard, D. Geffroy, D. Delroeux, J.M. Bereder, C. de Chaisemartin, Christophe Mariette, R. Kianmanesh, Pierre-Jean Valette, Jean-Jacques Tuech, M. H. Laverrière, B. Lelong, Guillaume Piessen, C. Labbé, Mehdi Karoui, S. Velasco, Guillaume Passot, Diane Goéré, V. Barrau, G. Balague, V. Loi, Olivier Glehen, P. Rousselot, Jean-Marc Regimbeau, Emilie Thibaudeau, Thomas Courvoisier, V. Verriele-Beurrier, Frédéric Bibeau, G. Desolneux, M. Chassang, Marc Pocard, Magali Svrcek, Jérémie H. Lefevre, J. Lacroix, O. Fay, Franck Zinzindohoué, Catherine Arvieux, Naoual Bakrin, Denis Pezet, A. Leroux, Cédric Nadeau, Charles Sabbagh, Romuald Wernert, Bruno Heyd, Pascale Mariani, S. Msika, S. Valmary-Degano, L. Ghouti, A. Thivolet, Clarisse Dromain, R. Kaci, G. Ferron, Pôle Information Médicale Evaluation Recherche (IMER), Hospices Civils de Lyon (HCL), Ciblage thérapeutique en Oncologie (EA3738), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Département de chirurgie, CRLCC Val d'Aurelle - Paul Lamarque, and Département de radiothérapie
- Subjects
MESH: Medical Records ,medicine.medical_specialty ,Scoring application ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Medical Records ,Peritoneal malignancy ,03 medical and health sciences ,Peritoneal Neoplasm ,0302 clinical medicine ,MESH: Patient Care Team ,Predictive Value of Tests ,Medicine ,Resectability ,MESH: Peritoneal Neoplasms ,Humans ,Stage (cooking) ,Peritoneal Neoplasms ,Neoplasm Staging ,Patient Care Team ,Internet ,MESH: Humans ,business.industry ,Medical record ,MESH: Peritoneum ,Reproducibility of Results ,General Medicine ,MESH: Neoplasm Staging ,Peritoneal cancer index ,MESH: Predictive Value of Tests ,3. Good health ,Surgery ,MESH: Reproducibility of Results ,MESH: Internet ,Oncology ,030220 oncology & carcinogenesis ,Predictive value of tests ,Conventional PCI ,Peritoneal Cancer Index ,030211 gastroenterology & hepatology ,Radiology ,Peritoneal diseases ,Extent disease ,Peritoneum ,business ,Peritoneal carcinomatosis ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology - Abstract
International audience; Based on the importance of assessing the true extent of peritoneal disease, PeRitOneal MalIgnancy Stage Evaluation (PROMISE) internet application (www.e-promise.org) has been developed to facilitate tabulation and automatically calculate surgically validated peritoneal cancer index (PCI), and other surgically validated scores as Gilly score, simplified peritoneal cancer index (SPCI), Fagotti and Fagotti-modified scores. This application offers computer-assistance to produce simple, quick but precise and standardized pre, intra and postoperative reports of the extent of peritoneal metastases and may help specialized and non-specialized institutions in their current practice but also facilitate research and multicentre studies on peritoneal surface malignancies.
- Published
- 2016
- Full Text
- View/download PDF
8. OA12.03 Activity of Crizotinib in MET or ROS1 Positive (+) NSCLC: Results of the AcSé Trial
- Author
-
J. Mazieres, Radj Gervais, C. Mahier Ait Oukhatar, Ratislav Bahleda, Frederique Nowak, Christos Chouaid, Denis Moro-Sibilot, S. De Guibert, P.J. Souquet, Renaud Sabatier, V. Verriele, Gilbert Ferretti, Bertrand Mennecier, Maurice Pérol, Gilles Vassal, Nathalie Cozic, S. Bota, Véronique Haddad, M. Wislez, and J. Otto
- Subjects
0301 basic medicine ,Pulmonary and Respiratory Medicine ,Oncology ,medicine.medical_specialty ,Crizotinib ,business.industry ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Internal medicine ,ROS1 ,medicine ,business ,medicine.drug - Published
- 2018
- Full Text
- View/download PDF
9. Sarcome du chorion cytogène de bas grade
- Author
-
L. Catala, V. Verriele, C. Morand, N. Paillocher, S. Abadie-Lacourtoisie, A. Lortholary, and P. Descamps
- Subjects
medicine.medical_specialty ,Hysterectomy ,Endometrial stromal sarcoma ,Uterine sarcoma ,business.industry ,medicine.medical_treatment ,Standard treatment ,Obstetrics and Gynecology ,Metrorrhagia ,General Medicine ,medicine.disease ,Gastroenterology ,Surgery ,Reproductive Medicine ,Internal medicine ,medicine ,Sarcoma ,Hormone therapy ,medicine.symptom ,business ,Etoposide ,medicine.drug - Abstract
Endometrial stromal sarcoma is a rare malignant uterine tumor. We report 4 cases of low-grade endometrial stromal sarcoma, corresponding to the form with a mitotic index at less than 10 mitoses per 10 high power fields (HPF), from which we carried out a review of the literature and defined the potential interest of hormone therapy and chemotherapy by etoposide. Generally diagnosed in pre-menopause, the main clinical signs, which are not very specific, are metrorrhagia and pelvic pain. The etiologic diagnosis is established from the pathology analysis. Intravascular extension, which is observed in nearly 50% of patients, should evoke the disease. The initial treatment is mainly based open surgery, generally total hysterectomy with annexectomy. There is no effective adjuvant treatment. The potential of reccurences remains around 50% with a 34-month median. Several therapeutic options are possible after recurrence but no standard treatment has been established. We are mainly interested in three medical options but the surgery remains an alternative of choice. Chemotherapy by oral etoposide offers easy administration, good compliance and acceptable toxicity with median 20-month remission in 3 patients before progression. Hormone therapy with progestogens (hormone receptor expression of the tumor is 71% for estrogens and 95% for progesterone) is widely studied in the literature with a 46% response rate and 46% rate of disease stabilization. Hormone therapy with an anti-aromatase appears to be a promising treatment according to the bibliographic references on this subject. Overall, prognosis of low-grade endometrial sarcoma is relatively good with 100% survival at 5 years. The progression pattern is slow, requiring regular and prolonged surveillance.
- Published
- 2005
- Full Text
- View/download PDF
10. HISTOLOGICAL FEATURES OF LARGE BONE ALLOGRAFTS
- Author
-
F. Gouin, V. Verriele, Norbert Passuti, Joel Delecrin, and J. V. Bainvel
- Subjects
medicine.medical_specialty ,Pathology ,Bone allograft ,medicine.diagnostic_test ,business.industry ,Histology ,Lower limb ,Surgery ,Bone transplantation ,Biopsy ,medicine ,Orthopedics and Sports Medicine ,Femur ,Inflammatory infiltration ,Woven Bone ,business - Abstract
We performed biopsies during reoperation for minor complications in two active young patients 9 and 19 months after massive bone allograft implantation for bone tumour. The grafts were dead and resorption-apposition activity, when present, was predominantly in subperiosteal areas. Inflammatory infiltration was very seldom found. Features considered as ‘microfractures’ or ‘microcracks’ were noted in the cortical ring together with the formation of woven bone, in areas with remodelling. Such cracks are likely to be of mechanical origin and do not inevitably lead to complications.
- Published
- 1996
- Full Text
- View/download PDF
11. Cœr et mort subite du nourrisson. Étude anatomopathologique de 100 cas
- Author
-
V Verriele, B Pelletier-Leroy, A Mouzard, and M F Nomballais
- Subjects
Gynecology ,medicine.medical_specialty ,business.industry ,Pediatrics, Perinatology and Child Health ,Medicine ,business ,Infant newborn ,Sudden death ,Sudden infant death - Abstract
Resume Les investigations post mortem completes ou l'autopsie tient une place majeure sont essentielles pour comprendre la cause et/ou le mecanisme du deces au cours des morts subites du nourrisson (MSN). Le but de cette etude est d'envisager l'apport de l'examen anatomopathologique du cœur dans la MSN. Population et methodes . — Cent sioxante-deux cas de mort subite du nourrisson ont ete autopsies entre 1981 et 1990 au CHU de Nantes. Cent dossers on ete retenus pour cette etude restrospective qui a comporte un nouvel examen macroscopique et microscopique (moyenne de 11 prelevements pour chaque cœur). Resultants . — Le poids des cœurs des nourrissons n'etat pas augmente des facon notable, sauf dans un cas. L'etude macroscopique n'a jamais retrouve de malformation cardiaque. L'examen histologique a permis de retrouver les lesions observees lors du premier examen de ce cœur dans 11 cas sur 100 et d'affiner nos connaissances sur les lesions histopathologiques du cœur au cours de la MSN. Conclusions . — Les lesion cardiaques observees sont probablement responsables des deces des nourrissons. Cette etude souligne l'importance de prelevement multiples et de l'examen microscopique de nombreuses coupes sur chaque cœur.
- Published
- 1995
- Full Text
- View/download PDF
12. Impact of immunohistochemical markers, CK5/6 and E-cadherin on diagnostic agreement in non-invasive proliferative breast lesions
- Author
-
G, MacGrogan, L, Arnould, I, de Mascarel, A, Vincent-Salomon, F, Penault-Llorca, M, Lacroix-Triki, F, Bibeau, M C, Baranzelli, V, Fridman, M, Antoine, V, Bécette, V, Brouste, J, Jacquemier, S, Mathoulin-Pélissier, and V, Verriele
- Subjects
medicine.medical_specialty ,Pathology ,Histology ,Mammary gland ,Lobular carcinoma ,Breast Neoplasms ,Pathology and Forensic Medicine ,Diagnosis, Differential ,Cytokeratin ,Biomarkers, Tumor ,Medicine ,Humans ,Breast ,Hyperplasia ,business.industry ,Carcinoma in situ ,Anatomical pathology ,General Medicine ,Ductal carcinoma ,medicine.disease ,Cadherins ,Immunohistochemistry ,medicine.anatomical_structure ,Carcinoma, Intraductal, Noninfiltrating ,Keratins ,Female ,business - Abstract
Aims: To assess the impact of cytokeratin (CK) 5/6 and E-cadherin immunohistochemistry on diagnostic agreement of non-invasive proliferative breast lesions. Methods and results: Twenty pathologists classified 105 cases of non-invasive proliferative breast lesions into 10 diagnostic categories. One haematoxylin and eosin (H&E) slide of each case was analysed on a first round and one H&E slide with corresponding CK5/6 and E-cadherin immunohistochemistry was analysed on a second round. Interobserver reproducibility for category-specific and management-specific lesions was measured on each round. CK5/6 and E-cadherin had little impact on diagnostic agreement, which remained moderate between the first and second rounds (overall κ coefficients of 0.47 and 0.53, respectively, P = NS). Levels of agreement slightly improved for lesions with specific CK5/6 and E-cadherin immunoprofiles (usual ductal hyperplasia, atypical ductal hyperplasia, atypical lobular hyperplasia, lobular carcinoma in situ, non-high-grade ductal carcinoma in situ), but the differences observed were not statistically significant. However, diagnostic agreement improved when lesions were grouped according to their management category (overall κ coefficients of 0.58 and 0.66 in the first and second rounds, respectively). Conclusions: CK5/6 and E-cadherin immunohistochemistry has little impact on interobserver reproducibility for non-invasive breast lesions. Diagnostic agreement can, however, be improved by grouping lesions in management categories.
- Published
- 2008
13. Metastatic gastric cancer arising from breast carcinoma: endoscopic ultrasonographic aspects
- Author
-
P. Maillart, P. Burtin, C. Binelli, G. Bertrand, G. Lorimier, V. Verriele, and E. Fondrinier
- Subjects
Pathology ,medicine.medical_specialty ,Linitis plastica ,Lobular Breast Carcinoma ,Breast Neoplasms ,Metastasis ,Endosonography ,Linitis Plastica ,Fatal Outcome ,Stomach Neoplasms ,medicine ,Carcinoma ,Humans ,Aged ,Retrospective Studies ,medicine.diagnostic_test ,business.industry ,Stomach ,Gastroenterology ,Echogenicity ,Middle Aged ,medicine.disease ,Combined Modality Therapy ,digestive system diseases ,Endoscopy ,Carcinoma, Lobular ,medicine.anatomical_structure ,Female ,Radiology ,Neoplasm Recurrence, Local ,business ,Breast carcinoma ,Follow-Up Studies - Abstract
Linitis plastica of the stomach was diagnosed in four patients. Endoscopic ultrasonography (EUS) was performed in four cases; they were monitored by EUS and had their treatment adapted accordingly, According to the present study, the typical criteria of gastric linitis at EUS are: (a) rigidity of the gastric wall; (b) a wall thickness exceeding 6 mm; (c) a second enlarged layer marginally more echogenic than the fourth hypoechogenic layer (muscularis propria); (d) a third hyperechogenic enlarged layer; and (e) a poor demarcation between layers. Gastric linitis appears more likely to be specific metastasis from lobular breast carcinoma. In most of the follow-up cases, EUS showed correlation with a subsequent decrease of the CA15.3 level. At present, EUS seems to be the most effective and least invasive examination for clinical diagnosis and treatment surveillance of secondary gastric linitis arising from infiltrating lobular carcinoma (ILC) of the breast.
- Published
- 1999
14. Prognostic and predictive value of HER2, PR, ER, and KI67 in the PACS01 trial comparing epirubicin-based chemotherapy to sequential epirubicin followed by docetaxel
- Author
-
Henri Roché, V. Verriele, Frédéric Bibeau, Marie-Christine Baranzelli, Christine Sagan, Jocelyne Jacquemier, Anne-Laure Martin, Yves Denoux, Magali Lacroix-Triki, and Frédérique Penault-Llorca
- Subjects
Oncology ,Gynecology ,Cancer Research ,medicine.medical_specialty ,Chemotherapy ,business.industry ,medicine.medical_treatment ,medicine.disease ,Predictive value ,Breast cancer ,Docetaxel ,Internal medicine ,Medicine ,In patient ,business ,Epirubicin ,medicine.drug - Abstract
605 Background: To define the value of biopathological parameters as prognostic and predictive markers in patients (pts) with node positive, operable breast cancer involved in the phase III trial P...
- Published
- 2005
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.